SOURCE: XTend Medical Corporation
|
October 22, 2009 08:30 ET
XTend Medical (XMDC) Updates Shareholders on Merger and Company's Progress
Management to Travel to Korea to Finalize Merger
SUN VALLEY, CA--(Marketwire - October 22, 2009) - XTend Medical (PINKSHEETS: XMDC), a company
specializing in manufacturing and distributing the latest in telemedicine
and diagnostic devices, released the following information regarding the
company's progress on merger and company's progress:
"XTend would like to update our shareholders on our progress to date. Mr.
Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with
the executives of XTend. The meetings were very positive and included
several aspects in the manufacturing process and the business model moving
forward. I personally want to thank Mr. Lee for his dedication and efforts
in moving the merger forward. The management of XTend will be traveling to
Korea soon to meet with the executives of BioHarp, Korea to finalize the
merger. We also intend to secure the manufacturing relationships Mr. Lee
has worked on over the past months in order to fulfill our needs for the
BioHarp unit. Mr. Lee has identified several major manufacturers that can
handle the volume of devices we'll need to fulfill the commitments we
expect over the next 6-12 months and having strategic manufacturing
partners in Korea to work closely with the technical staff is imperative to
the success of the company. While in Korea, XTend management will also be
looking to secure a listing on the Korean Stock Exchange that will add to
our shareholder base on a global basis and gain additional exposure for the
company.
The combined efforts of the seasoned technical team in Korea with the
management in the U.S. will insure that the BioHarp device will become the
standard in medical diagnosis. Our intention is to market the product
aggressively throughout Asia, the U.S. and Europe. To date, we've had over
7 inquiries from medical device companies looking to represent the BioHarp
in 4 different countries globally. As we move forward, these opportunities
will be explored and if they benefit the company, we will press forward on
a working relationship.
As to the BioHarp unit itself, I would like to reiterate a few areas that
make this device unique:
1. The BioHarp requires a pre-scan of the patient in order to get a
baseline reading. This baseline reading is not based solely on a set of
standards in the medical sector. These individualized baselines are
established from the patient's own cellular makeup and further solidify how
the BioHarp sets itself apart from any present of future competitors.
2. The BioHarp device is completely portable. Unlike CT Scanners and
other large pieces of equipment that remain stationary, the BioHarp can
travel to where the patients are. The unit is perfect for rural areas,
battlefields, or other outlying areas that would benefit by having the
BioHarp as part of their healthcare service.
3. BioHarp can be used to detect cellular inflammation in plants.
Diseases in crops have risen dramatically over the years and the BioHarp
can assist scientists in helping to determine the proper course of
treatment in order to insure plants can sustain life. The global percussion
in this area can be tremendous for the company.
4. The dedication Mr. Lee has spent on this device over the past 14 years
is truly incredible. His vision for this device has proven instrumental in
the development of the BioHarp. His technical staff has, and continues t,
spend countless hours perfecting this product and we feel honored to become
part of this exciting and truly unique product.
In closing, I would like to thank all of our shareholders for being patient
as we close this merger. Mr. Lee and I have worked continuously over the
past two years to insure you, as shareholders, will reap the benefits of
being part of something we're very proud of. The future is very bright for
this company and through hard work and dedication, the BioHarp will
flourish and become the leading diagnostic device in the global medical
community," stated Mr. Paul D. Lisenby, CEO of XTend Medical.
About XTend Medical
XTend Medical is a company that specializes in the manufacturing and
distribution of the latest in telemedicine and telehealth solutions for the
healthcare industry. Their dedication to insuring the products and services
offered to healthcare organizations, third-world countries, and physician
groups are at the forefront of medical technology. Their continued efforts
in identifying global companies with true product potential in the
healthcare industry puts them in an advantageous position to capitalize on
a global basis. For further information, please contact them at
info@bioharpunius.com
The new website can be located at www.bioharpunius.com
Forward-Looking Statements
This press release may contain forward-looking statements covered within
the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements relate to, among other things, plans and timing
for the introduction or enhancement of our services and products,
statements about future market conditions, supply and demand conditions,
and other expectations, intentions and plans contained in this press
release that are not historical fact and involve risks and uncertainties.
Our expectations regarding future revenues depend upon our ability to
develop and supply products and services that we may not produce today and
that meet defined specifications. When used in this press release, the
words "plan," "expect," "believe," and similar expressions generally
identify forward-looking statements. These statements reflect our current
expectations. They are subject to a number of risks and uncertainties,
including, but not limited to, changes in technology and changes in
pervasive markets.